Inhalation Sciences receives new order worth 41,000 Euro from returning big pharma customer

Stockholm, Sweden – April 15, 2025 – Inhalation Sciences AB (ISAB) has received a purchase order from a recurring global customer. The order, valued at 41,000 EUR, includes additional instruments and complementary equipment for advanced inhalation research.

This repeat business strengthens ISAB’s long-term relationship with the customer and further confirms the trust in the company’s technology and expertise within inhalation research.

"The fact that a global player once again chooses to invest in our technology is a strong validation of the quality and precision our systems deliver. We see this as a confirmation of our long-term collaboration and the strategic importance of our products in inhalation research. The order reinforces ISAB’s position as a leading provider of preclinical inhalation research technology and confirms the growing demand for our solutions”, says Manoush Masarrat, CEO of Inhalation Sciences.

For more information, please contact:

Manoush Masarrat, CEO
Mobile: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

Läs mer på Cision